Trial reportBlood2013
Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.
Trial report in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06211452 (Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia - Results of the Randomized GATLA 8-LMA-P'07 Trial), which is not on this map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia - Results of the Randomized GATLA 8-LMA-P'07 Trial
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Paediatric acute myeloid leukaemia epidemiology, treatment approaches, and outcomes in africa: A review of the literature.BMC cancer · 2025Pooled it
- Meta-ethnography of experiences of early discharge, with a focus on paediatric febrile neutropenia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Pooled it
- Systematic review of reduced therapy regimens for children with low risk febrile neutropenia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Pooled it
- Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia.Pediatric blood & cancer · 2018Trial
- Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Trial
- AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML Chemotherapy.JCO oncology practice · 2026Article
- CARE study: prospective cohort study on supportive care among paediatric oncology patients in western Kenya-a study protocol.BMJ open · 2026Article
- Treatment Outcomes and Factors Affecting Survival in Pediatric Acute Myeloid Leukemia.Annals of hematology · 2026Article
- Low survival in younger adults with Acute Myeloid Leukemia (AML) in Tanzania linked to high disease burden and socioeconomic factors.PloS one · 2025Article
- Healthcare professional perspectives following implementation of an infection management care pathway for pediatric patients with cancer: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Neutrophil Granulopoiesis Optimized Through Ex Vivo Expansion of Hematopoietic Progenitors in Engineered 3D Gelatin Methacrylate Hydrogels.Advanced healthcare materials · 2024Article
- Analysis of the incidence, characteristics, and risk factors of complications during induction chemotherapy in children with high-risk neuroblastoma.European journal of pediatrics · 2024Article
- Analysis of early and treatment related deaths among children and adolescents with acute myeloid leukemia in Poland: 2005-2023.Frontiers in pediatrics · 2024Article
- Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia.The Journal of molecular diagnostics : JMD · 2023Article
- Ethnic disparities in childhood leukemia survival by border residence: A Texas population-based analysis.Cancer · 2023Article
- Central-line-associated bloodstream infections and central-line-associated non-CLABSI complications among pediatric oncology patients.Infection control and hospital epidemiology · 2023Article
- Neutropenia and Infection Prophylaxis in Childhood Cancer.Current oncology reports · 2022Review
- SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients.European journal of cancer (Oxford, England : 1990) · 2021Observational
- Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.Pediatric blood & cancer · 2021Article
- Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia.JAMA network open · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 3 countries.
Funding
Abstract
Objective was to describe the effect of antibiotic and granulocyte colony-stimulating factor (G-CSF) prophylaxis and discharge policy on infection risk and nonrelapse-related mortality (NRM) during chemotherapy for children with acute myeloid leukemia. Patients were non-Down syndrome children enrolled on Children's Oncology Group (COG) trial AAML0531. We surveyed sites to determine institutional standards for systemic antibacterial, antifungal, and G-CSF prophylaxis, and mandatory hospitalization during neutropenia. COG institution survey response rate was 180 of 216 (83.3%). Of 1024 patients enrolled on AAML0531, 897 were non-Down patients from survey-responding institutions. In multiple regression, antibacterial prophylaxis reduced any sterile-site bacterial infection (incidence rate ratio [IRR] 0.85; 95% confidence interval [CI], 0.72-1.01; P = .058) and Gram-positive sterile-site infection (IRR 0.71; 95% CI, 0.57-0.90; P = .004). Prophylactic G-CSF reduced bacterial (IRR 0.79; 95% CI, 0.67-0.92; P = .004) and Clostridium difficile infections (CDIs; IRR 0.46; 95% CI, 0.25-0.84; P = .012). Mandatory hospitalization did not reduce bacterial/fungal infection or significantly reduce NRM but did increase CDI (IRR 1.96; 95% CI, 1.34-2.87; P < .001). Antibacterial and G-CSF prophylaxis reduced infection rates while mandatory hospitalization did not reduce infection or significantly affect NRM. This trial was registered at www.clinicaltrials.gov as #AAML0531.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.